MAPT and Alzheimer disease: Studies suggest that CSF biomarkers can serve as an early diagnostic tool for AD before cognitive impairment becomes apparent, by detecting Aβ42 and p-Tau in the CSF, AD can be identified at an earlier stage (de Leon et al., 2004; Papaliagkas et al., 2023).